CriticalHMG-CoA reductase inhibitors (statins)×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
The enzyme CYP3A4 metabolises simvastatin (simvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS), and voriconazole is a strong inhibitor of this enzyme (voriconazole SmPC, European Medicines Agency, EMA). The pair has not been studied, but the voriconazole SmPC says that voriconazole is likely to raise levels of statins metabolised by CYP3A4, which may lead to rhabdomyolysis (EMA). The simvastatin SmPC lists voriconazole among strong CYP3A4 inhibitors, that is, drugs that increase the area under the concentration–time curve (AUC) about 5-fold or more. Itraconazole, from the same list, raised exposure to the active form of simvastatin more than 10-fold (AEMPS). The higher the simvastatin level in the blood, the higher the risk of muscle damage (AEMPS).
Symptoms
The main risk is myopathy: muscle pain, tenderness or weakness with creatine kinase (CK) more than ten times the upper limit of normal (simvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Myopathy sometimes progresses to rhabdomyolysis, with or without acute kidney failure due to myoglobin in the urine, and very rarely deaths have occurred (AEMPS). Warning signs are unexplained muscle pain, tenderness or weakness, especially with malaise or fever. The risk rises with the simvastatin dose (simvastatin label, US Food and Drug Administration, FDA).
Management
The combination is contraindicated. The simvastatin documents list voriconazole among the strong inhibitors of the enzyme CYP3A4 that must not be taken with simvastatin (simvastatin summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, and simvastatin label, US Food and Drug Administration, FDA). If voriconazole cannot be avoided, stop simvastatin for the whole voriconazole course and consider another statin (AEMPS, FDA). The voriconazole documents are less strict: if combination with statins metabolised by CYP3A4 cannot be avoided, they suggest considering a lower statin dose (voriconazole SmPC, European Medicines Agency, EMA) and frequent monitoring for statin adverse reactions (voriconazole label, FDA). For simvastatin, however, the contraindication in its own documents applies. No document says when simvastatin can be restarted after voriconazole is stopped. According to the voriconazole SmPC, its half-life does not predict elimination because of non-linear pharmacokinetics (EMA). If muscle pain, weakness or cramps appear during statin treatment, measure CK and stop simvastatin if CK is above five times the upper limit of normal without strenuous exercise (AEMPS). Also stop it whenever myopathy is suspected (AEMPS, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- FDA: Zocor (simvastatin) tablets – Prescribing Information (2025)– FDA, DailyMed SPL, Organon, sections 2.5, 4, 5.1 and 7.1
- AEMPS: Ficha técnica: Simvastatina (nº registro 65199), sección 4.3 (2026)– AEMPS, CIMA, nº registro 65199, revisión 03/2026, sección 4.3
- AEMPS: Ficha técnica: Simvastatina (Zocor 20 mg) (nº registro 58846), secciones 4.3, 4.4 y 4.5 (2026)– AEMPS, CIMA, nº registro 58846, revisión 06/2026, secciones 4.3, 4.4 y 4.5
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº 02212015 (EU/1/02/212), secciones 4.2, 4.4 y 4.5, consultado 10/2026